

UNITED STATES PATENT APPLICATION

ANGIO-IMMUNOTHERAPY

Inventor: Eli Gilboa
Durham, North Carolina, USA

Smita Nair
Morrisville, North Carolina USA

David Boczkowski
Morrisville, North Carolina USA

Assignee: Duke University

Entity: Small

JENKINS, WILSON & TAYLOR, P.A.
Suite 1400, University Tower
3100 Tower Boulevard
Durham, North Carolina 27707
Telephone: 919-493-8000
Facsimile: 919-419-0383

"Express Mail" mailing number.: EV314782901US
Date of Deposit July 3, 2003
I hereby certify that this correspondence is being deposited
with the United States Postal Service "Express Mail Post
Office to Addressee" service under 37 C.F.R. 1.10 on the
date indicated above and is addressed to the Commissioner
for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.



Patty Wilson

ANGIO-IMMUNOTHERAPY

RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Patent Application Serial No. 60/393,599, filed July 5, 2002; the disclosure of which is incorporated herein by reference in its entirety.

TECHNICAL FIELD

[0002] The present invention relates to cancer therapy and, in particular, to a method of treating cancer that involves inducing active immunity against an endothelial-specific product preferentially expressed during tumor angiogenesis or against a factor that contributes to the angiogenic process.

BACKGROUND

[0003] Despite the many advances in the field of tumor treatment, cancer remains a major cause of morbidity and mortality. Various active immunotherapy approaches have been developed to induce immune responses to tumor antigens. However, clinical use of these strategies has been limited by challenges such as tolerance to self antigens on tumor cells, the emergence of immunological escape variants and the need to identify potent and broadly expressed antigenic targets.

[0004] One approach to immunotherapy that addresses these challenges is the use of antigen presenting cells transfected with tumor RNA. Methods for treating cancers using antigen-presenting cells loaded with RNA are disclosed in United States Patent Nos. 6,306,388 and 5,853,719 and related patents and applications.

[0005] Another approach to tumor therapy is the inhibition of angiogenesis. Angiogenesis is the formation of new blood vessels by capillary sprouting from pre-existing vessels. Endothelial cells are normally quiescent and seldom proliferate. In certain physiological processes (e.g., wound healing, hair growth, ovulation and embryogenesis), as well as in pathologic processes (e.g., diabetic retinopathy, psoriasis, atherosclerosis, rheumatoid arthritis, obesity and cancer), proliferation of endothelial cells and neoangiogenesis increase dramatically.

[0006] All tumors beyond a minimal size require blood supply and depend on intratumor neoangiogenesis. Increased blood flow to the tumor is necessary for its continued growth. Recent advances in the understanding of the molecular mechanisms underlying the angiogenic process and its regulation have led to the development of anti-angiogenic therapies for the treatment of cancer^{32, 34}.

[0007] Angiostatin and endostatin represent two potent and specific angiogenesis inhibitors that are generated by post translational cleavage from larger precursors, plasminogen and collagen XVIII, respectively. Anti-tumor activity of angiostatin and endostatin has been demonstrated in murine studies. The use of angiogenesis inhibitors in the treatment of angiogenesis-dependent diseases, such as cancer, is described in United States Patent Nos. 5,733,876; 5,854,205; 5,792,845; 6,174,861; 6,544,758 and related patents.

[0008] Passive monoclonal antibody-based therapies have also been proposed as a means to inhibit tumor angiogenesis. Monoclonal antibodies specific to various angiogenesis associated antigens, such as vascular endothelial growth factor (VEGF), vascular endothelial growth factor receptor (VEGF-R), and integrins and their use as inhibitors of angiogenesis have been described in United States Patent Nos. 6,524,583; 6,448,077; 6,416,758; 6,365,157 and 6,342,219.

[0009] Another intensive area of anti-angiogenic research and development involves the use of small molecular inhibitors^{32, 34}. These inhibitors are designed to interfere with key pathways that define the angiogenic process.

[0010] The leading group of anti-angiogenic agents under development is targeted to matrix metalloproteases (MMPs). Several MMP inhibitors have demonstrated modest clinical benefit as well as undesirable side effects. Small molecule inhibitors which target VEGF and VEGF-R are also under development²⁴.

[0011] Vascular endothelial growth factor (VEGF) and its receptors (VEGFR) play a critical role during angiogenesis and thus they are excellent targets for therapeutic interventions. VEGFR-2 is expressed exclusively in endothelial cells during angiogenesis and is the major transducer of VEGF mediated signals in endothelial cells leading to cell proliferation and migration. The importance of VEGFR-2 signaling for tumor angiogenesis was suggested by the observation that a dominant negative mutant of VEGFR-2 prevented tumor growth in mice²⁶. VEGFR-2 is up-regulated in tumor-associated endothelial cells but not in the vasculature of the surrounding tissue²⁷⁻³⁰. In view of the specificity of VEGFR-2 expression in proliferating endothelial cells at sites of angiogenesis and the key role of VEGFR-2 signaling during angiogenesis, interference with VEGFR-2 signaling represents a logical target for the development and clinical testing of anti-angiogenic therapies³¹⁻³⁴.

[0012] Tie2, like VEGFR-2, is a receptor tyrosine kinase upregulated on proliferating endothelial cells and following engagement with its ligand angiopoietin-1, transmits a proangiogenesis signal^{25,34}. Gene knockout and inhibition studies have shown that Tie2 function is essential during embryogenesis³⁵ and tumor neoangiogenesis³⁶⁻³⁸.

[0013] VEGF, the ligand for VEGFR-2, is an endothelial-specific growth factor and is essential for angiogenesis^{24,31}. Targeted inactivation of the

VEGF gene in mice causes abnormal blood vessel development and lethality in embryos^{39,40}. Unlike VEGFR-2 or Tie2, VEGF is expressed in stromal cells during angiogenesis^{24,31}. VEGF also plays an essential role during tumor angiogenesis as shown by the fact that inhibition of VEGF function suppresses tumor growth in mice⁴¹. The majority of human and murine tumors induce the expression of VEGF^{24,31} in response to the progressively hypoxic conditions in the growing tumor⁴². Indeed, tumors are the main source of VEGF during tumor angiogenesis^{24,31}. Thus VEGF can serve a dual role as an antigen to target both the tumor and its vasculature.

[0014] The Id proteins are a family of four related proteins implicated in the control of differentiation and cell cycle progression. Id1 and Id3 are co-expressed temporally and spatially during murine neurogenesis and angiogenesis and are not expressed in the adult normal tissues of murine and human origin. Id1 and Id3 are reexpressed in the microvasculature of growing tumors and studies in knockout mice have demonstrated that both Id1 and Id3 are required for angiogenesis and vascularization of tumor xenografts. Thus, these molecules present other potential targets for anti-angiogenic therapy.

[0015] While current anti-angiogenic therapies for cancer patients have shown some efficacy, the effect is cytostatic rather than cytotoxic. Inhibiting neo-angiogenesis prevents the growth of bulky tumors and may reduce tumor size but it does not eliminate micrometastatic disease. In addition, the use of polypeptide inhibitors presents manufacturing, stability and cost issues. Thus, there remained a need to find more effective tumor therapies that comprise an anti-angiogenic component, alone or in combination with other immunotherapeutic approaches. The present invention addresses that need and provides a novel and effective cancer therapy.

SUMMARY OF THE INVENTION

[0016] The present invention, termed angio-immunotherapy, provides a novel anti-angiogenic composition and method based on active immunization against angiogenesis-related antigens. The term “angiogenesis-related

antigen(s)" is used herein to refer to endothelial-specific products that are preferentially expressed during tumor angiogenesis or factors that contribute to the angiogenic process. While the passive administration of specific angiogenesis inhibitors has been described, there have been no previous reports of active immunization against angiogenesis-related antigens.

[0017] The present invention further provides a novel therapeutic modality that combines anti-angiogenic therapy and active immunotherapy. The two approaches are compatible therapeutic treatments that provide a synergistic effect.

[0018] In one aspect of the invention there is provided a composition for the treatment or prevention of cancer. The composition comprises a plurality of antigen presenting cells transfected with nucleic acid encoding at least one angiogenesis-related antigen.

[0019] The antigen presenting cells are preferably dendritic cells and the angiogenesis-related antigen is preferably selected from the group consisting of Id1, VEGFR-2, Tie2 and VEGF.

[0020] In a particularly preferred embodiment, dendritic cells are further transfected with nucleic acid encoding at least one tumor antigen. The nucleic acid may be total mRNA from tumor cells or synthetic mRNA encoding a selected tumor-associated antigen.

[0021] In another aspect of the invention, a method for the prevention or treatment of cancer is provided. The method comprises obtaining antigen presenting cells from a patient in need of therapy, introducing into those antigen presenting cells *in vitro* RNA encoding an angiogenesis-related antigen, thereby producing RNA loaded antigen presenting cells, and administering the RNA loaded antigen presenting cells to the patient.

[0022] In a preferred embodiment, RNA encoding a tumor antigen is also introduced into the antigen presenting cells thereby producing RNA loaded antigen presenting cells which are capable of presenting both angiogenesis-related antigen and tumor antigen. The tumor RNA and the angiogenesis-related RNA may be introduced at the same time or sequentially.

[0023] In another aspect of the invention, RNA loaded antigen presenting cells are prepared as described above. The RNA loaded antigen presenting cells are then contacted with T lymphocytes to generate immune cells *in vitro*. The *in vitro* generated CTL are then administered to the patient. As used herein the term "immune cells" refers to cytotoxic T cells, helper T cells, B cells, NK cells and other immune modulating cells.

[0024] Objects and advantages of the present invention will be clear from the description that follows.

BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 is a graph demonstrating the inhibition of lung metastases in mice immunized with DC transfected with Idl mRNA;

[0026] Figure 2 is a graph illustrating the effect on lung weight of co-immunization with Idl and B16 tumor RNA transfected DC;

[0027] Figure 3 is a graph illustrating the induction of CTL activity in mice immunized with dendritic cells transfected with VEGF and VEGFR-2 mRNA;

[0028] Figure 4 illustrates the inhibition of angiogenesis in mice immunized against angiogenesis-associated products;

[0029] Figure 5A illustrates inhibition of tumor growth after immunization with DC transfected with VEGF, VEGFR-2 and Tie2 mRNA in a melanoma model;

[0030] Figure 5B illustrates inhibition of tumor growth after immunization with DC transfected with VEGF, VEGFR-2 and Tie2 mRNA in a bladder tumor model;

[0031] Figure 6A shows the results of combination therapy with B16 tumor antigens and Tie2;

[0032] Figure 6B illustrates the results of combination therapy with MBT-2 mRNA or TERT MRNA and VEGF or VEGFR-2;

[0033] Figure 6C illustrates the time to appearance of palpable tumors;

[0034] Figure 7A illustrates the results of immunotherapy of tumor bearing mice with DC transfected with angiogenesis-associated and tumor antigens as indicated by tumor size at 18 days post-transplantation;

[0035] Figure 7B illustrates the results of immunotherapy of tumor bearing mice with DC transfected with angiogenesis-associated and tumor antigens as indicated by tumor size at 25 days post-transplantation;

[0036] Figure 7C illustrates the time to appearance of palpable tumors in mice receiving a combination of VEGFR-2 and TRP-2;

[0037] Figure 7D illustrates the time to appearance of palpable tumors in mice receiving a combination of VEGF and TRP-2;

[0038] Figure 8A illustrates the effect of immunization with VEGFR-2 mRNA transfected DC on fertility in mice at one week after the final immunization; and

[0039] Figure 8B illustrates the effect of immunization with VEGFR-2 mRNA transfected DC on fertility in mice at eight weeks after the final immunization.

DETAILED DESCRIPTION OF THE INVENTION

[0040] The present invention relates to a method of treating cancer that comprises inducing active immunity in a patient in need of such treatment against: i) an endothelial-specific product that is preferentially expressed during tumor angiogenesis, and/or ii) a factor that contributes to the angiogenic process. These endothelial-specific products and factor are jointly referred to herein as "angiogenesis-related antigens". The present invention takes advantage of the facts that i) an immune response can be stimulated against a normal gene product that is preferentially, although not necessarily exclusively, expressed in tumor microvasculature, ii) such a response inhibits tumor progression, and iii) significant toxicity (autoimmunity) does not result. The therapeutic approach of the present invention can be used in combination with other modalities for treating cancer such as radiation, chemotherapy and conventional immunotherapy.

[0041] In accordance with the present invention, active immunity can be induced using a variety of approaches. For example, angiogenesis-related antigens can be administered directly either as a composition (vaccine composition) comprising a single antigen type or as a composition comprising a mixture of different types of angiogenesis-related antigens. The antigens used can be produced chemically or recombinantly or the antigens can be isolated from natural sources.

[0042] Active immunity can also be induced in accordance with the invention by administering nucleic acid (RNA or DNA) encoding one or more angiogenesis-related antigen. The nucleic acid can be incorporated into a vector (e.g., a viral vector, such as an adenoviral vector, an adenoassociated

viral vector, or a vaccinia viral vector). Alternatively, the nucleic acid can be administered in association with a transfection facilitating agent, such as a liposome. Further, the nucleic acid (e.g., DNA present in plasmid) can be administered as naked nucleic acid (see, for example, USP 5,589,466) or it can be administered using a gene gun (that is, coated on a particle, such as a gold bead).

[0043] In a preferred embodiment, induction of active immunity is effected by administering to the patient antigen presenting cells (APCs) loaded with an angiogenesis-related antigen or transfected *in vitro* with nucleic acid (DNA or RNA) encoding at least one angiogenesis-related antigen.

[0044] Nucleic acid transfection can be effected using conventional techniques well known to those skilled in the art, such as lipid-mediated transfection, electroporation and calcium phosphate transfection. Peptide pulsing of APCs can be effected using art recognized methodologies. (See, for example, USP 5,853,719.)

[0045] Advantageously, the APCs are professional APCs, such as dendritic cells or macrophages. However, any APC can be used (e.g., endothelial cells or artificially generated APCs). While it is preferred that the cells administered to the patient be derived from that patient (autologous), APCs can be obtained from a matched donor or from a culture of cells grown *in vitro*. Methods for matching halotypes are known in the art.

[0046] The use of RNA-transfected APC's in the method of the invention is particularly advantageous, for example, over the use of protein/peptide pulsed APC's, for reasons that include ease of antigen generation. Given a sequence, the corresponding mRNA can be generated using, for example, RT-PCR and transcription, with cloning of the cDNA intermediate into bacterial plasmid an option but not prerequisite^{12, 13}. The

need to manufacture protein antigen or to identify class I and class II peptides corresponding to specific MHC alleles can thus be avoided.

[0047] Angiogenesis-related antigen-encoding nucleic acid for use in the invention can be isolated from natural sources (amplified as necessary) or synthesized chemically or recombinantly using conventional techniques.

[0048] Angiogenesis-related antigens suitable for use in the present invention include fetal or embryonic gene products re-expressed in tumor microvasculature (e.g., Id-1 and Id-2), VEGF receptors upregulated in the tumor microvasculature (e.g., VEGFR-2), and the endothelial specific product Tie-2. Angiopoietin-1 is another antigen that is useful in the present invention.

[0049] VEGF is expressed by the tumor stroma, the tumor itself or both. Therefore, VEGF is a prototype antigen that can elicit a dual immune response against both the tumor vasculature and the tumor or tumor stroma. Immunotherapy using VEGF, Id-1 and VEGF/Id-1 prototype antigens (or nucleic acids encoding same) can be particularly advantageous.

[0050] In accordance with the invention, active immunity can be induced against angiogenesis-related antigens alone or in combination with tumor antigens (e.g., TERT or total tumor derived antigenic mixture) (see USP 5,853,719).

[0051] The invention can be used to treat an existing tumor or prevent tumor formation in a patient (a human or non-human animal) (e.g., melanoma tumors, bladder tumors, breast cancer tumors, colon cancer tumors, prostate cancer tumors, and ovarian cancer tumors). It is preferable that treatment begin before or at the onset of tumor formation, and continue until the cancer is ameliorated. However, the invention is suitable for use even after a tumor has formed. In treating a patient in accordance to the invention, the optimal dosage depends on factors such as the weight of the patient, the severity of the cancer, and the nature of the antigen targeted.

[0052] When APCs are used, the dosage of cells is based on the body weight. Typically, a dosage of 10^5 to 10^8 cells/kg body weight, preferably 10^6 to 10^7 cells/kg body weight can be administered in a pharmaceutically acceptable excipient to the patient. The cells can be administered by using infusion techniques that are commonly used in cancer therapy. The optimal dosage and treatment regime for a particular patient can readily be determined by one skilled in the art by monitoring the patient for signs of disease and adjusting the treatment accordingly. The treatment can also include administration of mitogens (e.g., phyto-hemagglutinin) or lymphokines (e.g., IL-2 or IL-4) to enhance T cell proliferation.

[0053] The present invention demonstrates that combination of anti-angiogenic therapy and tumor immunotherapy of cancer is synergistic. Inhibition of angiogenesis by active immunotherapy to control tumor growth offers several attractive features. Firstly, active immunotherapy can induce a state of reduced angiogenic activity. Second, immunotherapy, like other anti-angiogenic strategies, provides multiple common targets, "universal" antigens, to inhibit tumor angiogenesis. In addition, due to the genetically stable nature and limited proliferative capacity of endothelial and stromal cells, emergence of antigen-loss or antigen processing-loss variants is significantly reduced compared to that of tumor cells. Furthermore, an especially attractive feature of anti-angiogenic immunotherapy is that it can be combined with tumor immunotherapy to deliver two distinct and potentially synergistic treatment modalities using a common procedure, immunization.

[0054] Immunization with mRNA-transfected DC is emerging as an efficient strategy to stimulate cellular immunity, and the present invention extends the use of this approach to angiogenesis-associated targets. A particularly useful feature of using mRNA-encoded antigens is the ease of isolating and generating mRNAs. cDNAs can be isolated from cells expressing the desired antigen by simple RT-PCR techniques and mRNA can be generated in pure form and in large quantities using cell-free enzymatic reactions. In the examples below, mRNA technology was used to study three

angiogenic targets, VEGFR-2, Tie2 and VEGF. It is readily apparent that the list can be readily expanded with candidates provided by the genomic revolution. Another advantage of the present invention is that the generation of mRNA-encoded antigens is comparatively simple and inexpensive, and the regulatory requirements are straightforward.

[0055] The feasibility of the present invention has been demonstrated in several experiments. While specific antigen and protocols have been used, it is clearly apparent that the invention can encompass other antigens and different assay methods.

[0056] As shown in Figure 1 and discussed further in Example 4, immunization with Id1 RNA transfected dendritic cells resulted in a significant reduction in lung metastases as compared to control animals. Figure 2 and example 5 illustrate that this anti-tumor effect can be augmented by co-immunization with Id1 RNA and B16 (tumor) RNA transfected dendritic cells.

[0057] As demonstrated in Figure 3 and discussed further in Examples 7 and 8, induction of CTL responses against VEGF and VEGFR-2 shows that it is possible to break tolerance against angiogenesis-associated targets. This leads to reduced angiogenic activity in the immunized animals as shown in Figure 4 and discussed in Examples 9 and 10. These results indicate that induction of immune response against VEGF and VEGFR-2 has potent anti-angiogenic effects.

[0058] Immunization against the angiogenesis-associated products VEGFR-2, Tie2 or VEGF was accompanied by inhibition of tumor growth in the B16/F10.9 melanoma metastasis and the MBT-2 bladder cancer models. Tumor inhibition was seen when mice were immunized before tumor challenge as shown in Figures 5 and 6 and discussed further in Examples 11 and 12. Tumor inhibition was also seen in the setting of pre-existing tumor burden, as discussed in Examples 13 and 14 and shown in Figure 7. Since VEGFR-2 or Tie2 are expressed in proliferating endothelial cells, but not in

MBT-2 or B16/F10.9 tumor cells, the observed tumor inhibition was an indirect consequence of interfering with the tumor neovascularization process. This conclusion is consistent with the observation that immunization against VEGFR-2 is accompanied by a reduced state of angiogenesis in the immunized animal. Unlike VEGFR-2 or Tie2, VEGF is expressed by stromal cells and tumor cells, including the B16/F10.9 and MBT-2 tumor cells used in this study. Thus, VEGF immunization may mediate its anti-tumor effect via inhibition of angiogenesis or direct antitumor immunity.

[0059] The experiments shown in Figure 6 and 7 establish the potential value of combining anti-angiogenic therapy and tumor immunotherapy. Immunization with syngeneic tumor RNA (B16/F10.9 or MBT-2) stimulates tumor-specific non-crossreactive protective immunity and thereby targets the tumor directly whereas immunization with VEGFR-2 or Tie2 mRNA targets the tumor vascularization process. As shown in Figure 6, mice immunized with both syngeneic tumor RNA and endothelial specific mRNA (VEGFR-2 or Tie2) exhibited a superior antitumor effect compared to mice immunized with either RNA alone. Furthermore, in the setting of pre-existing disease, co-immunization against tumor (TERT or TRP-2) and angiogenesis-specific (VEGFR-2) targets exhibited a pronounced inhibitory effect on tumor growth (Figure 5). These experiments also illustrate another key feature of inhibiting angiogenesis via active immunotherapy, namely the ability to deliver two compatible and synergistic cancer treatment modalities by a single protocol, immunization. Combination immunotherapy against VEGF and either TERT (Figure 6B), VEGFR-2 (Figure 7A) or TRP-2 (Figure 7B and 7D) was also synergistic, underscoring the value of targeting two defined and broadly expressed (“universal”) antigens. Although, in this instance it was not clear whether the contribution of VEGF was inhibition of angiogenesis, direct antitumor immunity or a combination of both.

[0060] A primary concern of immunizing against angiogenesis-associated products is interference with normal angiogenesis, especially if the effect is sustained. No significant adverse effects were seen in mice

immunized against angiogenesis-associated products in this and previous studies under conditions that significant antitumor effects were seen. As shown in Figure 8, no signs of morbidity or mortality were seen in the immunized animals except for a transient impairment of fertility in mice immunized against VEGFR-2, but not VEGF. These observations are consistent with previous studies which have shown that anti-angiogenic therapy exhibits differential susceptibility on tumor growth and wound healing 48,49, suggesting that a partial and transient reduction in angiogenic activity could suffice to impact on tumor growth without eliciting serious adverse effects. Furthermore, since functional immunological memory will require repeated immunizations 50,51, the persistence of an active anti-angiogenic immune response can be controlled simply by terminating vaccination.

[0061] The results described above demonstrate that anti-angiogenic immunotherapy is an effective anti-tumor modality. The effects seen with active immunization against angiogenesis related antigens can be augmented by combination with active immunization against tumor antigens. While specific antigens and protocols have been referred to herein, it is clearly apparent that other angiogenesis related antigens and tumor antigens will have similar effects.

[0062] The above disclosure generally describes the present invention. It is believed that one of ordinary skill in the art can, using the preceding description, make and use the compositions and practice the methods of the present invention. A more complete understanding can be obtained by reference to the following specific examples. These Examples are described solely to illustrate preferred embodiments of the present invention and are not intended to limit the scope of the invention. Changes in form and substitution of equivalents are contemplated as circumstances may suggest or render expedient. Other generic configurations will be apparent to one skilled in the art. All journal articles and other documents such as patents or patent applications referred to herein are hereby incorporated by reference.

EXAMPLES

[0063] Although specific terms have been used in these examples, such terms are intended in a descriptive sense and not for purposes of limitation. Methods of molecular biology, cell biology and immunology referred to but not explicitly described in the disclosure and these examples are reported in the scientific literature and are well known to those skilled in the art.

Example 1. Mice and murine cell lines

[0064] Mice. 4-6 weeks old C57BL/6 mice (H-2b) and C3H/HeN mice (H-2k) were obtained from the Jackson Laboratory, Bar Harbor, ME. In conducting the research described in this paper, the investigators adhered to the "Guide for the Care and Use of Laboratory Animals" as proposed by the committee on care of Laboratory Animal Resources Commission on Life Sciences, National Research Council. The facilities at the Duke vivarium are fully accredited by the American Association for Accreditation of Laboratory Animal Care.

[0065] Cell lines. The F10.9 clone of the B16 melanoma of C57BL/6 origin is a highly metastatic, poorly immunogenic and a low class I expressing cell line 16. EL4 is a thymoma cell line (C57BL/6, H-2b). The murine MBT-2 cell line, derived from a carcinogen-induced bladder tumor in C3H mice 17, was obtained from Dr. T. Ratliff (Washington University, St. Louis, MO). The SV40-transformed B6 fibroblast cell line, BLK.SV (TIB-88), was obtained from ATCC. Cells were maintained in DMEM supplemented with 10% fetal calf serum (FCS), 25 mM HEPES, 2 mM L-glutamine and 1 mM sodium pyruvate. Murine precursor-derived DC were generated in the presence of GM-CSF supernatant harvested from F10.9 cells transfected with the GM-CSF cDNA. Actively growing F10.9/GM-CSF cells were cultured in RPMI 1640 supplemented with 5% FCS, 1 mM Na pyruvate, .1 mM non-essential amino acids, 100 IU/ml penicillin, 100 µg/ml streptomycin and 5 x 10⁻⁵ M β-mercaptoethanol and 10 mM HEPES (complete RPMI) at 37°C and 5% CO₂. GM-CSF-containing supernatant was harvested after 24 h of capillary culture.

The GM-CSF supernatant was used to generate murine DC at a final dilution of 0.1%. The concentration of GM-CSF used was determined by ELISA.

Example 2. Preparation Of RNA Transfected Dendritic Cells

[0066] BMDC (bone marrow precursor-derived dendritic cells) were generated from bone marrow progenitors as previously described 18. Briefly, marrow from tibias and femurs of C57BL/6 mice were harvested followed by treatment of the precursors with ammonium chloride Tris buffer for 3 min at 37°C to deplete the red blood cells. The precursors were plated in RPMI-5% FCS with GM-CSF (15 ng/ml) and IL-4 (10 ng/ml, Peprotech (Rocky Hill, NJ). Cells were plated at 10⁶/ml and incubated at 37°C and 5% CO₂. 3 days later the floating cells (mostly granulocytes) were removed and the adherent cells replenished with fresh GM-CSF and IL-4 containing medium. 4 days later the non-adherent cells were harvested (immature day 7 DC), washed and replated at 10⁶/ml in GM-CSF and IL-4 containing medium. After 1 day the non-adherent cells were harvested, washed and electroporated with RNA.

[0067] Total RNA was isolated from actively growing tumor cell lines using the RNeasy kits (Qiagen) following the manufacturers protocols.

[0068] Electroporation was performed as previously described for human DC 19,20, with small modifications. Briefly, DC were harvested on day 8, washed and gently resuspended in Opti-MEM (GIBCO, Grand Island, NY) at 2.5 x 10⁷/ ml. The used DC culture media was saved as conditioned media for later use. Cells were electroporated in 2 mm cuvettes (200 µl of DC (5 x 10⁶ cells) at 300 V for 500 µs using an Electro Square Porator ECM 830, BTX, San Diego, CA). The amount of IVT RNA used was 2 µg and total tumor RNA was 10 µg, per 10⁶ DC. Cells were immediately transferred to 60 mm tissue culture petridishes containing a 1:1 combination of conditioned DC growth media and fresh RPMI-5% FCS with GM-CSF and IL-4. Transfected cells were incubated at 37°C, 5% CO₂ overnight, washed two times in PBS and then injected into mice.

Example 3. Tumor challenge models

[0069] B16/F10.9 melanoma model: DC were transfected with the various RNA preparations and naive, syngeneic mice were immunized intravenously with 5×10^5 precursor-derived DC per mouse in 200 μ l PBS, three times at 7-day intervals. Mice were challenged with 5×10^4 F10.9 cells intravenously 8-10 days after the final immunization. Mice were sacrificed based on the metastatic death in the control groups. Metastatic loads were assayed by weighing the lungs.

[0070] MBT-2 murine bladder tumor model: DC were transfected with the various RNA preparations and naive, syngeneic mice were immunized intravenously with 5×10^5 precursor-derived DC per mouse in 200 μ l PBS, three times at 7-day intervals. Mice were challenged with $2-5 \times 10^5$ MBT-2 cells subcutaneously (in the flank) 8-10 days after the final immunization. Tumor growth was evaluated every other day starting on day 6. Mice were sacrificed once the tumor size reached 20 mm.

[0071] For experiments testing synergy between different antigens, mice were immunized two times with 3×10^5 DC in 100 μ l for each antigen for a combined 6×10^5 DC in 200 μ l per mouse.

Example 4. Immunization against Id-1

[0072] Induction of protective anti-tumor immunity by immunization against Id1 was tested in the B16 melanoma experimental metastasis system. As described above, mice were first immunized and then challenged intravenously with B16 melanoma tumor cells (highly metastatic clone, F10.9 is used). 28 days later, the mice were sacrificed and the metastatic load in the lung was determined by weighing the lungs. As shown in Figure 1, immunization with B16 tumor RNA transfected DC causes a significant reduction in lung metastasis in this model. Immunization with Id1 RNA transfected DC also leads to a lower metastatic load.

Example 5. Combination therapy with Id1 and B16 RNA

[0073] To determine whether anti-Id1 and anti-tumor immunotherapy are synergistic, the same experimental protocol as described above was used with the exception that the intensity of immunization was reduced to two cycles from three cycles to better observe a difference between vaccination with tumor RNA and Id1+tumor RNA.

[0074] As shown in Figure 2, immunization with either Id1 or B16 RNA transfected DC inhibited lung metastasis in a significant manner confirming the results shown in Figure 1. Combination of Id1+B16 RNA vaccination is more potent, albeit not in a statistically significant manner. This may be because, in this particular experiment, two immunizations with tumor RNA resulted in a very significant reduction in tumor metastasis largely obscuring a potential additive effect of co-immunization with Id1.

Example 6. Preparation of VEGF, VEGFR-2, Tie2, TRP-2, telomerase and actin RNA

[0075] Creation of pSP73-Sph/A64. Oligonucleotides containing 64 A-T bp followed by an Spe I restriction site were placed between the EcoR I and Nar I sites of pGEM4Z (Promega) to create the plasmid pGEM4Z/A64. The Hind III-Nde I fragment of pGEM4Z/A64 was cloned into pSP73 (Promega) digested with Hind III and Nde I to create pSP73/A64. The plasmid pSP73-Sph was created by digesting pSP73/A64 with Sph I, filling in the ends with T4 DNA polymerase and re-ligating. pSP73-Sph/A64/Not contains a Not I restriction site adjacent to the Spe I site. C. Kontos (Duke University Medical Center, Durham, NC) generously provided plasmids containing murine VEGF, VEGFR-2 and Tie2. The cDNAs were amplified with Advantage DNA polymerase (Clontech) for cloning into pSP73-Sph.

[0076] Cloning of SP73-Sph/VEGF/A64. The forward primer 5' TATATATCTAGAGCCACCATGGCACCCACGACAGAAGGGAGAGCAGAAG -3' (SEQ ID NO: 1) and reverse primer 5'-TATATAGAATTCTCACCGCCTGGCTTGTACATC-3' (SEQ ID NO: 2) were

used to amplify a truncated version of the VEGF coding region, not including the signal sequence, from the plasmid and was cloned into the Xba I-EcoR I sites of pSP73-Sph/A64.

[0077] *Cloning of pSP73-Sph/VEGFR-2/A64.* VEGFR-2 was amplified in three reactions using the following primers: For bases 1-1420, 5'-TATATACTCGAGGCCACCATGGAGAGCAAGGCGATGC TAGCTG-3' (SEQ ID NO: 3) and 5'-ATTAATCTAGACTAGTTGGACTC AATGGGGCCTTC-3' (SEQ ID NO: 4). For bases 1420-2730, 5'-AATTAACTCGAGGCCACCATGGAAGTGACTGAAAGAGATGCAG-3' (SEQ ID NO: 5) and 5'-AAAAAAATCTAGATCAGCGCT CATCCAATTCATC-3' (SEQ ID NO: 6). For bases 2695-4390, 5'-ATATATCTCGAGGCCACCATGGATCCAGATGAATTGGATGAGCG-3' (SEQ ID NO: 7) and 5'-TATATATCTAGACTAACGAGCACCTCTCTC GTGATTT-3' (SEQ ID NO: 8). The fragments were cloned separately into the Xho I-Xba I sites of pSP73-Sph/A64.

[0078] *Cloning of pSP73/Tie2/A64/Not.* The forward primer 5'-TATATATCTAGAGGCCACCATGGACTCTTAGCCGGCTAGTTC-3' (SEQ ID NO: 9) and reverse primer 5'-TATATAGAATTCCCTAGGCTGCTTCCCGCAGAGCAG-3' (SEQ ID NO: 10) were used to amplify the Tie2 coding sequence from plasmid DNA. The fragment was cloned into the Xba I-EcoR I sites of pSP73/A64/Not.

[0079] *Cloning of pSP73-Sph/TRP-2/A64.* Total RNA was isolated from actively growing B16/F10.9 cells. Reverse transcription was primed with an anchored oligo dT primer and the TRP-2 cDNA was amplified from the first stand using the forward primer 5'-GATGGATCCAAGCTTGCACCACATGGGCCTTGTGGGATGG-3' (SEQ ID NO: 11) and the reverse primer 5'-GTTAGATCTGCGGCCGCTAGGCTTCCCGTGTATC-3' (SEQ ID NO: 12). The resulting product was digested with Bgl II and BamH I and cloned into the BamH I site of pSP73-Sph/A64.

[0080] *Cloning of pGEM4Z/murineTERT/A64.* The EcoR I fragment of pGRN188 (Geron Corp., Menlo Park, CA) was cloned into the EcoR I site of

pGEM4Z/A64/Not. Linearization with Not I followed by in vitro transcription (Ambion mMessage mMachine kit, Austin, TX) yields a transcript containing 61nt from of the polylinker of pGEM4Z, followed by 34 nt of 5' UTR of mTERT, 3366 nt mTERT ORF, 36 nt of 3' UTR of mTERT, 64 A residues, an Spe I site and a Not I half-site.

[0081] *Cloning of pGEM4Z/murine actin/A64.* Reverse transcription of total RNA from F10.9 cells was primed by oligo dT and carried out by PowerScript reverse transcriptase (Clontech). The forward primer 5'-TATATAAGCTTCTTGAGCTCCTCGTTG-3' (SEQ ID NO: 13) and the reverse primer 5'-TTTATGGATCCAAGCAATGCTGTCACCTTCCC-3' (SEQ ID NO: 14) were used to amplify the actin coding sequence from the first-strand cDNA. The PCR fragment was cloned into the Hind III-BamH I sites of pGEM4Z/A64.

Example 7. CTL induction *in vivo*

[0082] *Generation of CTL.* Bone marrow precursor derived DC were generated and transfected with RNA as described above. Naive, syngeneic mice were immunized intravenously with 5×10^5 precursor-derived DC per mouse in 200 μ l PBS, three times at 7-day intervals. Splenocytes were harvested 8-10 days after the final immunization and depleted of red blood cells with ammonium chloride Tris buffer. 10^7 splenocytes were cultured with 2×10^5 stimulator cells (DC electroporated with RNA) in 5 ml of IMDM with 10% FCS, 1 mM sodium pyruvate, 100 IU/ml penicillin, 100 μ g/ml streptomycin and 5×10^{-5} M β -mercaptoethanol per well in a 6-well tissue culture plate. The responders were stimulated with the same antigen as used for the immunization. Cells were cultured for 5 days at 37°C and 5% CO₂. Effectors were harvested on day 5 on Histopaque 1083 gradient prior to use in a CTL assay.

[0083] *In vitro cytotoxicity assay.* 5-10 $\times 10^6$ target cells were labeled with europium for 20 minutes at 4°C. 10^4 europium-labeled targets and serial dilutions of effector cells at varying E:T ratios were incubated in 200 μ l of

complete RPMI 1640. The plates were centrifuged at 500 g for 3 minutes and incubated at 37°C for 4 hours. 50 µl of the supernatant was harvested and europium release was measured by time resolved fluorescence ²¹. Specific cytotoxic activity was determined using the formula: % specific release = {(experimental release - spontaneous release)/(total release - spontaneous release)} x 100. Spontaneous release of the target cells was less than 25% of total release by detergent in all assays. Standard errors of the means of triplicate cultures was less than 5%.

Example 8. CTL activity in response to immunization with angiogenesis-related antigens

[0084] To determine whether immunization can break tolerance against angiogenesis-associated products, C57BL/6 mice were immunized with VEGFR-2 or VEGF mRNA-transfected syngeneic DC and CTL responses were measured in the splenocytic population following in vitro stimulation as described above. Targets used for CTL detection were syngeneic BLK.SV tumor cells (H-2^b) transfected with actin mRNA, VEGF mRNA or VEGFR-2 mRNA. BLK.SV cells, like most tumor cells, express VEGF as determined by RT-PCR (data not shown). As shown in Figure 3, immunization of mice with VEGF mRNA transfected DC stimulated CTL, which recognized all BLK.SV targets. Figure 3 demonstrates that only targets transfected with VEGFR-2 mRNA were recognized by CTL generated from mice immunized against VEGFR-2. This is consistent with the fact that BLK.SV tumor cells do not express VEGFR-2 (data not shown). In contrast, BLK.SV cells transfected with actin mRNA or other mRNAs, were not recognized by CTL generated from mice immunized against actin. This demonstrates that it is possible to break tolerance against VEGF or VEGFR-2, but not actin, despite the fact that they represent normal gene products. Presumably, this is due to the fact that VEGF and VEGFR-2, as well as many other angiogenesis-associated products, exhibit a restricted tissue-specific pattern of expression.

Example 9. Dorsal Skin-Fold Window Chamber Assay

[0085] Details of the design and surgical technique used for the mouse dorsal skin-fold window chamber assay are described elsewhere^{22,23}. Briefly, mice immunized with DC transfected with VEGF or VEGFR-2 or PBS were randomly divided into three groups. An investigator who was unaware of the experimental details carried out all remaining procedures and measurements. 5 days following the surgery for placing the window chambers, the mice were then implanted with tumor cells (B16/F10.9 cells expressing GFP). This approach ensured that there would not be any interference in interpretation from the vascular changes caused by surgery. Starting on day 4 post-tumor implantation the mice were evaluated for the effect of immunization on tumor growth and vascularization. Tumor areas were measured with low magnification images of the whole tumor. Tumor vasculature was evaluated based on four random tumor areas, using higher magnification (objective, x20). Image analysis software was used to measure the cumulative length of all vessels in focus in each image. The vascular length density was calculated by dividing the total vessel length density in the frame by the area of the frame. All images were calibrated against micrometer images at the same magnification.

Example 10. Measurement of neoangiogenesis using a skin flap window chamber model

[0086] To determine whether angiogenesis is inhibited in mice immunized against either VEGFR-2 or VEGF, the development of neovasculature in a small tumor implant was followed in real time using the skin flap window chamber model described above. Mice were either injected with PBS or immunized with VEGFR-2 or VEGF mRNA-transfected DC three times at weekly intervals. 4 weeks following the last immunization a window chamber was surgically implanted. 5 days later, B16/F10.9 melanoma cells expressing green fluorescent protein (GFP) (to facilitate subsequent analysis) were implanted into the window chamber. Invasion of blood vessels into the tumor area was monitored daily and quantitated by image analysis as

previously described²³. Figure 4 shows the invasion of blood vessels into the implanted GFP expressing (green - second and fourth columns in Figure 4) tumor mass. Mice injected with PBS exhibit a typical pattern of microvessel invasion into the implanted tumor, illustrative of normal angiogenesis. By contrast, a significant paucity of microvasculature was seen in the implanted tumors of mice immunized against either VEGFR-2 or VEGF. This illustrates that immunization against these antigens was associated with a partial inhibition of angiogenesis. The difference between control mice injected with PBS and mice immunized against the angiogenic products was confirmed using image analysis measuring time to microvessel invasion and microvasculature density (data not shown). The data shown in Figure 4 are representative of each group and of observations taken over time.

Example 11. Immunization against endothelial products and tumor antigens is synergistic

[0087] To determine whether the reduced rate of angiogenesis that was seen in mice immunized against angiogenesis-associated product affects tumor progression, inhibition of tumor growth in mice immunized against VEGFR-2, Tie2 or VEGF was tested in the B16/F10.9 melanoma experimental metastasis model¹⁶ and the subcutaneously implanted MBT-2 bladder tumor model^{11,17}. RT-PCR analysis confirmed that VEGF was expressed in both B16/F10.9 and MBT-2 tumor cells whereas neither VEGFR-2 nor Tie2 were expressed in either tumor (data not shown). In the experiment shown in Figure 5A, the B16/F10.9 experimental metastasis model was used to measure the impact of immunization on lung metastasis. The mRNAs corresponding to VEGF, VEGFR-2 or Tie2 were transfected into syngeneic bone marrow-derived DC and used to immunize C57BL/6 mice three times at weekly intervals. 8 days following the last immunization, mice were challenged intravenously with B16/F10.9 tumor cells and lung metastasis was determined 35 days later. Mice injected with PBS or immunized with DC transfected with murine actin mRNA were used as controls. As previously seen in this experimental system, immunization with B16/F10.9 tumor RNA-

transfected DC inhibited the development of lung metastasis (Figure 5A). Immunization with VEGFR-2 mRNA-transfected DC had a comparable anti-metastatic effect. On the other hand, the impact of immunization with either Tie2 or VEGF mRNA transfected DC was more pronounced. A similar pattern of tumor inhibition was seen in the MBT-2 bladder tumor model (Figure 5B). Since VEGFR-2 or Tie2 are expressed in proliferating endothelial cells and are not expressed in either MBT-2 or B16/F10.9 tumor cells, yet tumor growth is inhibited in mice immunized against each product, the observed inhibition of tumor growth must have been mediated via inhibition of tumor angiogenesis. This conclusion is supported by the observation that immunization against VEGFR-2 is accompanied by a reduced state of angiogenesis in the immunized animal.

Example 12. Combination anti-angiogenic and Immunotherapeutic treatments
[0088] To determine whether targeting the tumor for immunological destruction and simultaneously preventing tumor vasculature formation will exert a synergistic antitumor effect, B16/F10.9 and MBT-2 tumor RNA-transfected DC were used to stimulate an immune response directed against antigens expressed by the tumor cells. The source of tumor RNA was tissue cultured tumor cell lines devoid of normal cells such as endothelial cells. It also should be noted that the immune response elicited in mice immunized with tumor RNA-transfected DC is directed to unique, and not shared, tumor antigens as judged by the fact that no crossreactivity between the tumors has been observed ¹¹. Figure 6A shows that in the B16/F10.9 tumor model, co-immunization with B16/F10.9 tumor RNA and Tie2 mRNA is superior to immunization with either RNA alone. Similarly, Figures 6B and 6C show that in the MBT-2 model co-immunization with MBT-2 RNA and VEGFR-2 mRNA-transfected DC was superior to using either antigen alone, leading to a significant delay in tumor onset. These experiments demonstrate the value of combined immunization against tumor and its vasculature. The polypeptide component of telomerase (TERT), which is silent in normal tissues but reactivated in over 85% of cancers ⁴³, can serve as a broadly useful antigen in

cancer vaccination^{11,44,45}. It has previously been shown that immunization against TERT can elicit CTL and protective tumor immunity against several tumors of unrelated origin¹¹. Figure 6B further demonstrates that immunization of mice against both VEGF and TERT is superior to immunization against either VEGF or TERT alone suggesting that targeting the two broadly expressed prototype “universal” tumor antigens could improve the efficacy of antitumor vaccination. However, as noted above, since VEGF is also expressed by tumor cells, including the B16/F10.9 and MBT-2 tumor cells used in this study, it is not clear whether the antitumor effects of immunizing against VEGF reflect a direct effect on the tumor, its vasculature, or both.

Example 13. Immunotherapy for pre-existing disease

[0089] *B16/F10.9 melanoma model:* Mice were challenged with 1×10^4 F10.9 cells subcutaneously (in the flank). 3 days post-tumor implantation mice were immunized intravenously with 5×10^5 precursor-derived DC per mouse in 200 μ l PBS, three times at 7-day intervals. Tumor growth was evaluated every other day starting on day 10. Mice were sacrificed once the tumor size reached 20 mm.

[0090] For experiments testing synergy between different antigens, mice were immunized with 3×10^5 DC in 100 μ l for each antigen for a combined 6×10^5 DC in 200 μ l per mouse.

Example 14. Impact of anti-angiogenic and anti-tumor therapy on pre-existing disease

[0091] To determine the impact of antitumor and anti-angiogenic immunotherapy in the setting of pre-existing disease, mice were first implanted with B16/F10.9 tumor cells followed by the immunization protocol starting three days post-tumor implantation as described above. Figure 7A shows that in this setting, the effect of anti-VEGF immunotherapy was more pronounced than immunotherapy against TERT or VEGFR-2. Co-immunizing

the mice against TERT and VEGFR-2 or VEGF and VEGFR-2 was synergistic, exhibiting an enhanced antitumor effect. Figure 7B and 7C further demonstrate that co-immunization against another tumor-expressed antigen, TRP-2, a dominant antigen in B16 melanoma⁴⁶, and VEGF or VEGFR-2 is synergistic, leading to a significant delay in tumor growth.

Example 15. Effect of anti-angiogenic therapy on fertility

[0092] In two previous studies, mice immunized 10 days following immunization with VEGFR-2 protein loaded DC failed to become pregnant⁹, whereas mice immunized with an attenuated Salmonella vector encoding a VEGFR-2 cDNA exhibited a slight delay in wound healing but no impact on fertility¹⁰.

[0093] To determine whether the anti-tumor immunotherapies of the present invention have an effect on fertility, mice were immunized with DC electroporated with VEGF, VEGFR-2 or actin RNA three times at weekly intervals. 1 week and 8 weeks after the final immunization mice were mated with non-immunized male mice. This was done in triads (2 females to a male per cage). Number of pups delivered was recorded and the pups were examined for signs of sickness and abnormality and their weight post-weaning recorded.

[0094] In this study, despite reduced rate of angiogenesis seen in mice immunized against VEGFR-2 or VEGF no signs of morbidity or mortality were seen over an extended period of observation exceeding 6 months. However, a significant albeit transient impact on fertility of mice vaccinated against VEGFR-2, but not VEGF, was noted. As shown in Figure 8, mice vaccinated against VEGFR-2 and mated one week later failed to become pregnant whereas if mating was delayed for 8 weeks the VEGFR-2 immunized mice were fertile with litter sizes and average weight of offsprings comparable to non-immunized mice. These observations suggest that vaccination against angiogenesis-associated products can have transient adverse effects, presumably reflecting the limited persistence of an active anti-vascular

immune response. The reason for the differential effects of anti-VEGF and VEGFR-2 immunization on fertility (Figure 8A), despite a comparable inhibitory effect on angiogenesis (Figure 4), is unclear and will require additional studies. This suggests that in the setting of immunotherapy angiogenesis-associated products/antigens will exhibit a differential toxicity profile and that it may be possible to identify angiogenic targets which exhibit significant antitumor activity yet low toxicity.

Example 16. Statistics

[0095] The different experimental groups within the study were compared using the Kruskal-Wallis test. The Mann-Whitney U-test was used to determine significance in differences in lung weights between two groups. A probability of less than .05 ($P<.05$) was used for statistical significance. To determine the significance of combination therapy between tumor antigen and angiogenesis-related antigens we determined time to tumor onset (appearance of palpable tumors) for the various groups. Comparison between two groups were done using the log-rank test (Mantel-Haenszel test). Additional comparisons between two groups were done by determining the median time to tumor onset for each group.

[0096] All documents cited above are hereby incorporated in their entirety by reference. Also incorporated by reference are the following: Plum et al, Vaccine 19:1294 (2001), Niethammer et al, Proc. Am. Ass. Can. Res. 43:324 (2002), Li et al, J. Exp. Med. 195:1575 (2002), and Wei et al, Nat. Med. 6 (10) :1160 (2001).

1. Bailar JC, 3rd, Gornik HL. Cancer undefeated. *N Engl J Med.* 1997;336:1569-1574.
2. Gilboa E. The makings of a tumor rejection antigen. *Immunity.* 1999;11:263-270.
3. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. *Adv Immunol.* 2000;74:181-273
4. Rosenberg SA. Progress in human tumour immunology and immunotherapy. *Nature.* 2001;411:380-384.
5. Pardoll DM. Cancer vaccines. *Nat Med.* 1998;4:525-531.
6. Folkman J. Tumor angiogenesis: therapeutic implications. *N Engl J Med.* 1971;285:1182-1186.
7. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. *Cell.* 1996;86:353-364.
8. Wei YQ, Wang QR, Zhao X, Yang L, Tian L, Lu Y, Kang B, Lu CJ, Huang MJ, Lou YY, Xiao F, He QM, Shu JM, Xie XJ, Mao YQ, Lei S, Luo F, Zhou LQ, Liu CE, Zhou H, Jiang Y, Peng F, Yuan LP, Li Q, Wu Y, Liu JY. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. *Nat Med.* 2000;6:1160-1166.
9. Li Y, Wang MN, Li H, King KD, Bassi R, Sun H, Santiago A, Hooper AT, Bohlen P, Hicklin DJ. Active Immunization Against the Vascular

Endothelial Growth Factor Receptor flk1 Inhibits Tumor Angiogenesis and Metastasis. *J Exp Med.* 2002;195:1575-1584.

10. Niethammer AG, Xiang R, Becker JC, Wodrich H, Pertl U, Karsten G, Eliceiri BP, Reisfeld RA. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. *Nat Med.* 2002;8:1369-1375

11. Nair SK, Heiser A, Boczkowski D, Majumdar A, Naoe M, Lebkowski JS, Viweg J, Gilboa E. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. *Nature Medicine.* 2000;6

12. Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. *J Exp Med.* 1996;184:465-472

13. Nair SK, Boczkowski D, Morse M, Cumming RI, Lyerly HK, Gilboa E. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. *Nat Biotechnol.* 1998;16:364-369

14. Heiser A, Dahm P, D RY, Maurice MA, Boczkowski D, Nair SK, Gilboa E, Vieweg J. Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. *J Immunol.* 2000;164:5508-5514

15. Nair S, Boczkowski D. RNA-transfected dendritic cells. *Expert Rev. Vaccines.* 2002;1:89-95

16. Porgador A, Tzehoval E, Vadai E, Feldman M, Eisenbach L. Combined vaccination with major histocompatibility class I and interleukin 2

gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases. *Cancer Res.* 1995;55:4941-4949.

17. Soloway MS, deKernion JB, Rose D, Persky L. Effect of chemotherapeutic agents on bladder cancer: a new animal model. *Surg Forum.* 1973;24:542-544

18. Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, Muramatsu S, Steinman RM. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. *J Exp Med.* 1992;176:1693-1702.

19. Saeboe-Larsen S, Fossberg E, Gaudernack G. mRNA-based electrotransfection of human dendritic cells and induction of cytotoxic T lymphocyte responses against the telomerase catalytic subunit (hTERT). *J Immunol Methods.* 2002;259:191-203.

20. Van Tendeloo VF, Ponsaerts P, Lardon F, Nijs G, Lenjou M, Van Broeckhoven C, Van Bockstaele DR, Berneman ZN. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. *Blood.* 2001;98:49-56.

21. Volgmann T, Klein-Struckmeier A, Mohr H. A fluorescence-based assay for quantitation of lymphokine-activated killer cell activity. *J Immunol Methods.* 1989;119:45-51

22. Huang Q, Shan S, Braun RD, Lanzen J, Anyrhambatla G, Kong G, Borelli M, Corry P, Dewhirst MW, Li CY. Noninvasive visualization of tumors in rodent dorsal skin window chambers. *Nat Biotechnol.* 1999;17:1033-1035.

java/Propub/biotech/nbt1099_1033.fulltext
java/Propub/biotech/nbt1099_1033.abstract

23. Li CY, Shan S, Huang Q, Braun RD, Lanzen J, Hu K, Lin P, Dewhirst MW. Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. *J Natl Cancer Inst.* 2000;92:143-147.
24. Veikkola T, Alitalo K. VEGFs, receptors and angiogenesis. *Semin Cancer Biol.* 1999;9:211-220.
25. Gale NW, Yancopoulos GD. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. *Genes Dev.* 1999;13:1055-1066.
26. Millauer B, Longhi MP, Plate KH, Shawver LK, Risau W, Ullrich A, Strawn LM. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types *in vivo*. *Cancer Res.* 1996;56:1615-1620.
27. Olson TA, Mohanraj D, Carson LF, Ramakrishnan S. Vascular permeability factor gene expression in normal and neoplastic human ovaries. *Cancer Res.* 1994;54:276-280.
28. Berkman RA, Merrill MJ, Reinhold WC, Monacci WT, Saxena A, Clark WC, Robertson JT, Ali IU, Oldfield EH. Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. *J Clin Invest.* 1993;91:153-159.
29. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Dvorak HF, Senger DR. Increased expression of vascular permeability factor

(vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol. 1993;143:1255-1262.

30. Brown LF, Berse B, Jackman RW, Tognazzi K, Guidi AJ, Dvorak HF, Senger DR, Connolly JL, Schnitt SJ. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol. 1995;26:86-91.

31. Zhu Z, Witte L. Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor. Invest New Drugs. 1999;17:195-212

32. Deplanque G, Harris AL. Anti-angiogenic agents: clinical trial design and therapies in development. Eur J Cancer. 2000;36:1713-1724.

33. Eatock MM, Schatzlein A, Kaye SB. Tumour vasculature as a target for anticancer therapy. Cancer Treat Rev. 2000;26:191-204.

34. Cherrington JM, Strawn LM, Shawver LK. New paradigms for the treatment of cancer: the role of anti- angiogenesis agents. Adv Cancer Res. 2000;79:1-38

35. Hanahan D. Signaling vascular morphogenesis and maintenance. Science. 1997;277:48-50.

36. Lin P, Polverini P, Dewhirst M, Shan S, Rao PS, Peters K. Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth. J Clin Invest. 1997;100:2072-2078.

37. Lin P, Buxton JA, Acheson A, Radziejewski C, Maisonneuve PC, Yancopoulos GD, Channon KM, Hale LP, Dewhirst MW, George SE, Peters

KG. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proc Natl Acad Sci U S A. 1998;95:8829-8834.

38. Siemeister G, Schirner M, Weindel K, Reusch P, Menrad A, Marme D, Martiny-Baron G. Two independent mechanisms essential for tumor angiogenesis: inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway. Cancer Res. 1999;59:3185-3191.
39. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declercq C, Pawling J, Moons L, Collen D, Risau W, Nagy A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature. 1996;380:435-439.
40. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, Powell-Braxton L, Hillan KJ, Moore MW. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 1996;380:439-442.
41. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993;362:841-844.
42. Blancher C, Harris AL. The molecular basis of the hypoxia response pathway: tumour hypoxia as a therapy target. Cancer Metastasis Rev. 1998;17:187-194.
43. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer. 1997;33:787-791

44. Minev B, Hipp J, Firat H, Schmidt JD, Langlade-Demoyen P, Zanetti M. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. *Proc Natl Acad Sci U S A*. 2000;97:4796-4801.
45. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. *Immunity*. 1999;10:673-679.
46. Schreurs MW, Eggert AA, de Boer AJ, Vissers JL, van Hall T, Offringa R, Figdor CG, Adema GJ. Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model. *Cancer Res*. 2000;60:6995-7001.
47. Kerbel RS. A cancer therapy resistant to resistance. *Nature*. 1997;390:335-336.
48. Lange-Asschenfeldt B, Velasco P, Streit M, Hawighorst T, Pike SE, Tosato G, Detmar M. The angiogenesis inhibitor vasostatin does not impair wound healing at tumor-inhibiting doses. *J Invest Dermatol*. 2001;117:1036-1041.
49. Quinn TE, Thurman GB, Sundell AK, Zhang M, Hellerqvist CG. CM101, a polysaccharide antitumor agent, does not inhibit wound healing in murine models. *J Cancer Res Clin Oncol*. 1995;121:253-256
50. Matzinger P. An innate sense of danger. *Semin Immunol*. 1998;10:399-415
51. Bachmann MF, Kundig TM, Hengartner H, Zinkernagel RM. Protection against immunopathological consequences of a viral infection by

activated but not resting cytotoxic T cells: T cell memory without "memory T cells"? Proc Natl Acad Sci U S A. 1997;94:640-645.

[0098] It will be understood that various details of the presently claimed subject matter can be changed without departing from the scope of the presently claimed subject matter. Furthermore, the foregoing description is for the purpose of illustration only, and not for the purpose of limitation.